The primary advantage of being Duffy-negative is resistance to Plasmodium vivax malaria, one of the most widespread malaria parasites in the world. People who lack the Duffy protein on their red blood cells deny this parasite its main entry point, making infection far less likely. This trait is so beneficial in malaria-endemic regions that it has become nearly universal across sub-Saharan Africa through natural selection.
How the Duffy Protein Works
The Duffy protein, also called DARC (Duffy Antigen Receptor for Chemokines), sits on the surface of red blood cells and on cells lining blood vessels. It has two jobs: it acts as a docking site for the P. vivax malaria parasite, and it binds inflammatory signaling molecules called chemokines, helping regulate immune cell movement throughout the body.
People who are Duffy-positive carry one or both versions of this protein (known as Fya and Fyb). People who are Duffy-negative carry a genetic variant that silences Duffy protein production on red blood cells entirely. This variant, called FY*BES, is so common in sub-Saharan Africa that it has reached near-fixation across large stretches of the continent, meaning virtually everyone in some populations carries it.
Protection Against Vivax Malaria
P. vivax relies on the Duffy protein as its primary gateway into red blood cells. The parasite produces a surface molecule called Duffy-binding protein (PvDBP), which latches onto DARC to pull itself inside. Without DARC on the red blood cell surface, the parasite has no handle to grab. This effectively blocks the main invasion pathway.
For centuries, this protection appeared nearly absolute. Sub-Saharan African populations, where Duffy negativity is dominant, showed virtually no P. vivax transmission, a pattern so consistent that researchers long considered it a hard rule of malaria biology. The high prevalence of the Duffy-negative trait in these populations is itself evidence of how strong the selective pressure from vivax malaria has been over thousands of years.
That said, the protection is no longer considered complete. A systematic review identified 27 studies documenting P. vivax infections in Duffy-negative individuals across 13 African countries, including Ethiopia, Cameroon, Madagascar, and Kenya, as well as a few cases in Brazil and Iran. Researchers believe the parasite may be adapting to use alternative invasion pathways, possibly through mechanisms similar to those seen in related parasites. These cases remain relatively uncommon, but they signal that the advantage, while substantial, is not an ironclad guarantee.
Effects on Inflammation and Immune Signaling
Beyond malaria, being Duffy-negative changes how your body handles inflammation. The Duffy protein on red blood cells acts as a “sink” for inflammatory chemokines, soaking them up from the bloodstream. Without it, chemokine levels in the blood shift, and immune cell behavior changes in ways that can cut both directions.
On the potential upside, lacking DARC on blood vessel walls may reduce certain inflammatory cascading effects. Research in mice shows that overexpressing DARC on blood vessel cells actually enhanced inflammatory responses by helping shuttle chemokines to where circulating immune cells could detect them, promoting their movement into tissues. The Duffy protein on endothelial cells gets upregulated during infection, inflammation, and even organ transplant rejection, suggesting it actively amplifies the inflammatory process. Being Duffy-negative could theoretically dampen some of these responses.
On the downside, DARC-deficient mice showed exaggerated responses to certain bacterial toxins, indicating the protein also plays a role in fine-tuning immune reactions. The picture is complex: DARC appears to both buffer and facilitate inflammation depending on where it’s expressed and what type of immune challenge the body faces.
Lower Neutrophil Counts and Benign Ethnic Neutropenia
One well-documented consequence of being Duffy-negative is a lower white blood cell count, specifically neutrophils. This condition, called benign ethnic neutropenia, is common in people of African, Middle Eastern, and Caribbean descent. Affected individuals typically have an absolute neutrophil count between 1,000 and 1,500 cells per microliter, below the standard threshold of 1,500 that defines neutropenia on lab tests.
The word “benign” is important here. People with this trait don’t experience more frequent or more severe infections than anyone else. Their immune systems function normally. The main practical issue is that standard lab reference ranges were established using European-descended populations, so a Duffy-negative person’s routine blood work may flag as abnormal when it’s actually their healthy baseline. This can lead to unnecessary follow-up testing or delays in treatments like chemotherapy that require minimum neutrophil counts.
The HIV Tradeoff
The lower neutrophil counts associated with Duffy negativity do appear to carry one significant disadvantage. A study of high-risk South African women found that those with Duffy-null-associated low neutrophil counts (below 2,500 cells per microliter) had roughly a threefold greater risk of acquiring HIV and seroconverted about 2.4 times faster than other participants.
Interestingly, the relationship with HIV is not straightforward. Earlier research in an African American cohort found that while Duffy-negative individuals were more susceptible to acquiring HIV, those who did become infected showed a survival advantage compared to Duffy-positive individuals with HIV. The mechanism likely involves the same chemokine dynamics: DARC on red blood cells can act as a reservoir for HIV-attracting chemokines, potentially influencing how the virus interacts with immune cells at different stages of disease.
Given how common the Duffy-negative trait is across Africa, researchers have suggested it may be one of many biological factors contributing to the dynamics of the HIV epidemic on the continent.
Blood Transfusion Considerations
Being Duffy-negative also matters in transfusion medicine. If a Duffy-negative person receives blood from a Duffy-positive donor, their immune system may recognize the unfamiliar Duffy proteins as foreign and produce antibodies against them. This can happen after a transfusion, during pregnancy, or after an organ transplant.
These antibodies can cause hemolytic transfusion reactions, where the immune system destroys the donated red blood cells, and can also lead to hemolytic disease in a fetus during pregnancy. People with the fully Duffy-negative phenotype (Fy(a-b-)) may develop several different anti-Duffy antibodies, and once sensitized, they need Duffy antigen-negative, crossmatch-compatible blood for all future transfusions. This can create supply challenges, particularly in regions where the Duffy-negative phenotype is less common in the donor pool.
The Evolutionary Bottom Line
The advantage of being Duffy-negative is fundamentally a story about malaria. In regions where P. vivax was a major killer, losing the Duffy protein on red blood cells provided such a powerful survival benefit that the trait spread to near-universal prevalence over generations. The tradeoffs, including altered chemokine regulation, lower neutrophil counts, and potential shifts in HIV susceptibility, were not enough to outweigh the protection against a parasite that has shaped human genetics for millennia. Like sickle cell trait and other malaria-protective adaptations, Duffy negativity reflects the enormous evolutionary pressure infectious disease has placed on human biology.